To respond or not to respond to CD40 agonism: That is the prediction.
In the context of the clinical development of a CD40-stimulatory monoclonal antibody for the treatment of B-cell cancers, a tumor mRNA-based gene signature reflecting CD40 signaling pathway activation status was identified that could be used to predict responding and non-responding patients with diffuse large B cell lymphoma (DLBCL).
Molecular Diagnostics and Cancer Cell Biology; Genentech, Inc.; South San Francisco, CA USA.
Xiaoyan
X
Shi
David
D
Dornan